Results 161 to 170 of about 12,575 (207)
Some of the next articles are maybe not open access.
Clinical Pharmacokinetics of Darunavir
Clinical Pharmacokinetics, 2007Darunavir (TMC114) is a newly developed HIV-1 protease inhibitor with potent antiviral activity against both wild-type and multidrug resistant HIV-1 strains. The drug is currently approved by the US FDA for antiretroviral treatment-experienced patients with limited therapeutic options.
Michael, Rittweger, Keikawus, Arastéh
openaire +2 more sources
Enfermedades Infecciosas y Microbiología Clínica, 2008
The resistance profile of darunavir (DRV) was initially explored using pooled week 24 data from POWER 1, 2, and 3 at the recommended dose of DRV (n=467) with the subsequent addition of data from the placebo arm without etravirine (ETR) of DUET 1 and 2 (n=604).
openaire +2 more sources
The resistance profile of darunavir (DRV) was initially explored using pooled week 24 data from POWER 1, 2, and 3 at the recommended dose of DRV (n=467) with the subsequent addition of data from the placebo arm without etravirine (ETR) of DUET 1 and 2 (n=604).
openaire +2 more sources
Darunavir for the treatment of HIV infection
Expert Opinion on Pharmacotherapy, 2018Darunavir (DRV) was the last approved protease inhibitor (PI) and has been extensively used for the treatment of HIV in both naïve and experienced subjects due to its high genetic barrier and efficacy. The introduction in clinical practice of integrase strand transfer inhibitors limited its role in the management of naïve subjects and in antiretroviral
Vincenzo Spagnuolo +2 more
openaire +2 more sources